Advertisement

Topics

ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections

11:53 EDT 17 Apr 2019 | Investing News Network

ADMA Biologics (NASDAQ:ADMA) has announced it has been granted patent no. 10,259,865 from the US Patent and Trademark Office for treating S. pneumonia infection. As quoted in the press release: The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the … Continued

The post ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections appeared first on Investing News Network.

Original Article: ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections

NEXT ARTICLE

More From BioPortfolio on "ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...